Completed cases

Complaints considered by the Code of Practice Panel are judged on the evidence provided by both parties. Once concluded a case report is published on this website. Good compliance decisions rely on both the interpretation of the Code and an understanding of its application, published case reports help in this regard and set precedent in a particular set of circumstances. When making decisions on compliance with the Code, knowledge gained from previous case reports can be beneficial.                        

Search options for completed cases can be found below, please scroll down.

Please note that abbreviations/acronyms can only be searched under the Text search.

Where searching under clause number please look under sub clause where one exists, eg Clause 6.1 not just 6.

Click on the blue arrow below to search completed cases.  Searches can be run by free Text, Case number, Respondent, Complainant or Clause Number.

The results can then be filtered by: Year Received or Applicable Code Year. Results will be automatically ordered by 'Completed Date - Most Recent First', other options are available to select. 

The order of the results displayed can be changed by clicking in the box beside 'Order Results By'.

Please Note:

Cases can only link to clauses in the interactive 2019 or 2016 Codes.

 

 

 

Search completed cases

No summary as outwith the scope of the Code

No breach Clause(s): Outwith the scope of the Code

Applicable Code: 2016

Received: 12 September 2018

Completed: 03 July 2019

A contactable individual who described him/herself as a concerned UK health professional, complained about the Janssen Medical Cloud website.  The website was described on its homepage as being for healthcare professionals providing information about Janssen, product information, medical education and resources for patient management by disease area.  Links were included to prescribing information and the home page included that the website contained promotional content. The complainant stated that Janssen Medical Cloud appeared to be a website...

Applicable Code: 2016

Received: 27 February 2019

Completed: 27 June 2019

A complainant, who described him/herself as a concerned UK health professional, complained about a retweet from Novartis which had appeared in his/ her Twitter feed.  The tweet, originally sent by a clinician who had attended a Novartis meeting, read: ‘So many terrific talks at the @NovartisUK Haematology Masterclass meeting on recent advances in MPN, AML, CAR, ITP, AA, CML (attached pic of [name] giving an excellent plenary talk) and many more.  Haematology is such an exciting...

Applicable Code: 2016

Received: 27 February 2019

Completed: 18 June 2019

A named, non-contactable, current employee of Leo Pharma complained about some of the company’s promotional practices. The complainant was concerned that the company was breaching the Code because it: - encouraged representatives to visit doctors five times a year ie more often than the allowed 3 unsolicited visits; - did audits only for customers that used the company’s products; - did not put speaker slides through the medial legal approval process; - encouraged representatives not to report adverse...

No breach Clause(s): 2, 9.1, 9.9, 14.1, 15.6, 15.9, 19.1, 19.2

Applicable Code: 2016

Received: 19 February 2019

Completed: 18 June 2019

A complainant who described him/herself as a concerned UK health professional, complained about a tweet sent by Sanofi UK.  The tweet referred to Epilim (sodium valproate) and read:                ‘Today we spoke @IMMDSReview [the Independent Medicines and Medical Devices Safety Review].  We have fully engaged in assisting the Review team to consider the complex issue arising from the use of Epilim to treat women and girls of child-bearing potential suffering from epilepsy.’ Epilim was indicated for the treatment...

Applicable Code: 2016

Received: 27 February 2019

Completed: 11 June 2019

An anonymous, non-contactable health professional alleged that a Gilead Oncology Faculty Meeting held in Frankfurt in March 2018, constituted disguised promotion of Zydelig (idelalisib).  Zydelig was used in certain adult patients with either chronic lymphocytic leukaemia (CLL) or follicular lymphoma (FL). The complainant stated that it was only after arriving that he/she found out that the premise of the meeting was to train speakers on Zydelig and for them then to go out and speak about...

Applicable Code: 2016

Received: 19 April 2019

Completed: 03 June 2019

A contactable complainant who described him/ herself as a Servier employee complained about an advisory board on the management of metastatic colorectal cancer (mCRC) held on 23 June 2017.  Servier marketed Lonsurf (trifluridine/tipiracil) which was used in certain patients with mCRC. The complainant noted that advisory boards were meant to seek answers to unknown questions.  The complainant alleged that from the beginning, two senior managers decided that the representatives should influence which health professionals should be...

Applicable Code: 2016

Received: 05 February 2019

Completed: 30 May 2019

A complainant who described him/herself as a concerned UK health professional, complained about two almost identical emails from Merck Sharp & Dohme, received within minutes of each other.  The emails were headed ‘Explore MSD Connect Today’ and invited recipients to access the latest information about Merck Sharp & Dohme products, support their patients with online resources and sign-up for online and live events.  The complainant noted that the two emails had different subject lines (‘Diabetes 101...

Applicable Code: 2016

Received: 18 February 2019

Completed: 28 May 2019

A complainant who described him/herself as a concerned UK health professional complained about the Eli Lilly rheumatology website (www. lillyrheumatology.co.uk) stating that it was unclear whether the site was promotional or a resource for health professionals.  On reaching the website the complainant confirmed that he/she was a health professional and initially the content appeared to focus on congresses and medical educational activities.  However, under the ‘our products’ tab there was information on Olumiant (baricitinib) and...

Applicable Code: 2016

Received: 04 November 2018

Completed: 25 May 2019

An individual who described him/herself as a ‘concerned UK health professional’, complained about the Dr Falk Pharma website for health professionals and links from that website.  The complainant referred to information provided for Budenofalk (budesonide, used to treat, inter alia, Crohn’s disease), Salofalk (mesalazine, used to treat ulcerative colitis), Ursofalk (ursodeoxycholic acid, used to treat, inter alia, primary biliary cirrhosis) and Jorveza (budesonide, used to treat eosinophilic esophagitis). The complainant noted that on the webpages for...

Applicable Code: 2016

Received: 04 February 2019

Completed: 24 May 2019

About 1212 result(s)